Results 271 to 280 of about 311,988 (356)

Stem cell therapy in systemic sclerosis. [PDF]

Clin Rheumatol
Sakkas LI, Simopoulou T, Alexiou I, Liaskos C, Chikanza IC.   +4 more
europepmc   +1 more source

Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis. [PDF]

, 2008
Jimenez, Sergio A., Rosenbloom, Joel
core   +1 more source

Impact of evolving treatment patterns on interstitial lung disease progression in systemic sclerosis using the EUSTAR database

Arthritis &Rheumatology, Accepted Article.
Background The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasing immunosuppressive (IST) and anti‐fibrotic therapies available. However, their real‐world use remains unclear. Objectives To analyze treatment trends and the effect of IST and anti‐fibrotic therapies on ILD progression ...
Corrado Campochiaro, Marie‐Elise Truchetet, Madelon Vonk, Giacomo De Luca, Giovanna Cuomo, Lidia P. Ananieva, Eric Hachulla, Vanessa Smith, Ana Maria Gheorghiu, Radim Becvar, Patricia Carreira, Nicolas Hunzelmann, Daniel E. Furst, Vera Ortiz‐Santamaria, Francesco Del Galdo, Marco Matucci‐Cerinic, Anna‐Maria Hoffmann‐Vold, EUSTAR collaborators   +17 more
wiley   +1 more source

Scleroderma Clinical Trials Consortium Classification Criteria for Systemic Sclerosis Heart Involvement

Ross L, Burns AT, La Gerche A, Hansen D, Coghlan JG, Stevens W, Prior D, Pham A, McKelvie P, Bellocchi C, Braun Moscovici Y, Bruni C, Carreira P, Frech T, Hoa S, Hudson M, Hsu V, Low AHL, Matucci-Cerinic M, Medina Fonseca B, Ng S, Rodriguez Reyna T, Sahhar J, Talaat M, Proudman S, Vacca A, Baron M, Nikpour M.   +27 more
europepmc   +1 more source

Development of a conceptual model of early systemic sclerosis (scleroderma). [PDF]

Orphanet J Rare Dis
Lenderking WR, Ladd MK, Barnes N, Braverman J, Gasior M, Hofmann J, Lawo JP, Khanna D.   +7 more
europepmc   +1 more source

Systemic Lupus Erythematous Emergence in a Multiple Sclerosis Patient Treated with Fingolimod

, 2017
Amir Neshatfar
openalex   +1 more source

National Mortality Databases to Assess Disease Burden in Systemic Autoimmune Diseases: A Valuable Resource But With Limitations

Arthritis &Rheumatology, EarlyView.
Ram Raj Singh
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Arthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta   +4 more
wiley   +1 more source

GLUT and FAPα as molecular markers for interstitial lung disease in systemic sclerosis. [PDF]

Respir Res
Broens B, van der Laken CJ, Radonic T, Nossent EJ, Manz XD, Mulder DJ, Al-Adwi Y, Gan CT, Timens W, Voskuyl AE, Duitman JW.   +10 more
europepmc   +1 more source

Measuring the Impact: MRI Response of Sacroiliac Joints to TNF Inhibitors in Youth with Axial Disease

Arthritis &Rheumatology, Accepted Article.
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes in youth with axial juvenile spondyloarthritis (axJSpA) initiating TNF inhibitor (TNFi).
Timothy G. Brandon, Rui Xiao, Daniel J. Lovell, Edward Oberle, Matthew L. Stoll, Nancy A. Chauvin, Michael L. Francavilla, Walter P. Maksymowych, Pamela F. Weiss   +8 more
wiley   +1 more source